OUR STORY
2011 : une idée
Resulting from the research of Professor Christian Auclair, University Professor (PRCE), Doctor of Pharmacy, PhD in Science, and CNRS researcher, our first formulation was created in 2011. It was designed to address a major medical need: relieving skin inflammations caused by radiotherapy in patients with breast cancer.
2012 : premier test
Between 2012 and 2014, several clinical trials were conducted in Europe to evaluate the therapeutic potential of DQ5® and to confirm the relevance of its development.
These studies were carried out in cancer patients treated with radiotherapy or targeted therapies, under the supervision of Professor E. Deutch, Head of the Radiotherapy Department at the Gustave Roussy Institute — one of the largest cancer centers in Europe — and Professor E. Raymond, Head of the Interhospital Oncology Department at Beaujon Hospital.
2020 : La naissance d
BioSelvans was founded in 2020 in Strasbourg, within the Quest for Health incubator (formerly SEMIA), with the support of the Grand Est Region and Bpifrance.
The ambition was clear: to bring back to France a project initially developed in Switzerland, in order to anchor it sustainably within the local health innovation ecosystem.
2022 : Premier essai clinique
In 2022, under the leadership of Professor Walter Gubelin, dermatologist and opinion leader in Latin America, a clinical trial was conducted with 30 patients with breast cancer or head and neck cancer who had developed radiodermatitis.
Registered and approved by an ethics committee, this study demonstrated a significant improvement in various skin parameters as well as a notable gain in quality of life for the patients.
2024 : L'enregistrement
The remarkable results of the clinical trial led Professor Gubelin to initiate the registration of the solution under cosmetic status, in order to accelerate its availability to patients.
In December 2023, the formulation was officially registered in Chile as a cosmetic product. Shortly thereafter, around twenty exploratory tests were conducted on various inflammatory skin conditions, with very promising results.
In November 2024, the formulation obtained its cosmetic registration in Europe, marking a decisive milestone and paving the way for its large-scale commercialization.
2025 : Le lancement
Today, we are reaching a major milestone with the commercialization of our first innovative solution, specifically developed to support women facing severe skin lesions during their radiotherapy treatment for breast cancer.
Thanks to a simple, effective, and skin-friendly formula, this solution helps relieve symptoms and significantly improve comfort and quality of life for patients throughout this challenging period.